Sustiva
The summary of product characteristics for Sustiva (efavirenz: Bristol-Myers
Squibb) now states that Sustiva must not be administered concurrently
with voriconazole because efavirenz decreases voriconazole plasma concentrations
while voriconazole also increases efavirenz plasma concentrations. See
SPC.